Encorafenib (13) is for unresectable or metastatic melanoma patients with BRAF V600E or BRAF V600K mutation and treat metastatic colorectal cancer (mCRC) patients with BRAF V600E mutation (combined with cetuximab). The gene discussed is BRAF; the disease is metastatic melanoma.